BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19417624)

  • 1. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study.
    Wei S; Said-Al-Naief N; Hameed O
    Appl Immunohistochem Mol Morphol; 2009 Oct; 17(5):393-402. PubMed ID: 19417624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver.
    Nash JW; Morrison C; Frankel WL
    Arch Pathol Lab Med; 2003 Dec; 127(12):1591-5. PubMed ID: 14632573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
    Buxant F; Engohan-Aloghe C; Noël JC
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):254-7. PubMed ID: 19875955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen and progesterone receptor expression in the mammary gland tumors.
    Moise M; Buruian MM; Ilie C; Zamfir CL; Folescu R; Motoc AG
    Rom J Morphol Embryol; 2013; 54(4):961-8. PubMed ID: 24398991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical evaluation of hormone receptors with predictive value in mammary carcinomas.
    Pleşan DM; Georgescu M; Georgescu CV; Pătrană N; Nină T; Pleşan C
    Rom J Morphol Embryol; 2011; 52(4):1331-6. PubMed ID: 22203942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.
    Clark BZ; Beriwal S; Dabbs DJ; Bhargava R
    Am J Clin Pathol; 2014 Jul; 142(1):64-71. PubMed ID: 24926087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors].
    Sundblad AS; Caprarulo L
    Medicina (B Aires); 1996; 56(6):683-9. PubMed ID: 9284572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors.
    Sica G; Wagner PL; Altorki N; Port J; Lee PC; Vazquez MF; Saqi A
    Arch Pathol Lab Med; 2008 Dec; 132(12):1889-95. PubMed ID: 19061285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
    Keshgegian AA; Cnaan A
    Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
    Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
    Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
    Lee BH; Hecht JL; Pinkus JL; Pinkus GS
    Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
    Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
    Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
    Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
    Breast; 2014 Dec; 23(6):754-62. PubMed ID: 25176593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.